Articles tagged "Infection"

2022 American Transplant Congress
Phenytoin To Expedite Sirolimus & Tacrolimus Elimination: A Case Report
A. Lemke, B. A. Boilson, R. Razonable, S. A. Bernard
Mayo Clinic, Rochester, MN
*Purpose: Sirolimus (SIR), a mammalian target of rapamycin inhibitor (mTORi), may be used with or without a calcineurin inhibitor after heart transplant (HT). The anti-proliferative…
2022 American Transplant Congress
Incidence and Outcomes of CMV Infection in Pancreas Transplant with Thymoglobulin Induction: A Single Center Experience
W. Abusalah, A. Yadav
Thomas Jefferson University Hospital, Philadelphia, PA
*Purpose: CMV infection is a major infectious complication in pancreas transplant recipients (PTR). Incidence of CMV viremia in PTR with thymoglobulin induction and it's effect…
2022 American Transplant Congress
Infections in Kidney Transplant Recipients on Belatacept versus Tacrolimus-Based Immunosuppression
S. Gattis¹, A. Basu²
¹Emory Healthcare, Atlanta, GA, ²Emory University Hospital, Atlanta, GA
*Purpose: Patients 70 years and older with advanced/ end stage kidney disease are increasingly receiving kidney transplants. Immediately post- transplant, our center utilizes Belatacept coupled…
2022 American Transplant Congress
Lung Transplantation For Covid-19: An International Registry
M. G. Ison¹, R. Giris², O. Dias³, R. Vos⁴, J. Magnusson⁵, T. Zangeneh⁶, E. D. Lease⁷, S. Aslam⁸, M. Weder⁹
¹Northwestern University Comprehensive Transplant Center, Chicago, IL, ²Spectrum Health, Grand Rapids, MI, ³Einstein Hospital, Buenos Aires, Argentina, ⁴UZ Leuven, Leuven, Belgium, ⁵Sahlgrenska Transplant Centre, Stockholm, Sweden, ⁶University of Arizona, Tucscon, AZ, ⁷University of Washington, Seattle, WA, ⁸University of California San Diego, San Diego, CA, ⁹University of Virginia, Charlottesville, VA
*Purpose: SARS-CoV-2 can result in a range of infections from asymptomatic disease to progressive COVID-19 and death. In some patients with COVID-19 Lung Disease (C19LD),…
2022 American Transplant Congress
Vitamin D Status and Sars-cov-2 Infection in a Cohort of Renal Transplanted Patients
A. Regalia, C. M. Alfieri, M. Campise, D. Cresseri, M. Gandolfo, P. Messa, G. Castellano
Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico Milano, Milano, Italy
*Purpose: Immunomodulatory and anti-inflammatory properties have been hypothesized for native vitamin D (nVD). Very little is reported about nVD and risk of Sars-CoV-2 infection (COV)…
2022 American Transplant Congress
The Effectiveness of Healthcare-Associated Infections Prevention Measures in the Incidence of Infections and In-Hospital Mortality After Liver Transplantation: A Quasi-Experimental Single-Center Study
C. Bittante¹, L. R. Requião-Moura², F. Menezes¹, S. Morgado¹, L. Correa³, L. Camargo²
¹Hospital Israelita Albert Einstein, São Paulo, Brazil, ²Universidade Federal de São Paulo, São Paulo, Brazil, ³Universidade Federal de São Paulo, Sao Paulo, Brazil
*Purpose: To evaluate the effectiveness of multifaceted control interventions (bundles) aimed at preventing multiple healthcare-associated infections (HAI) in liver transplant recipients.*Methods: This quasi-experimental study enrolled…
2022 American Transplant Congress
Clinical Features and Outcomes of Hospitalized Solid Organ Transplant and Hematopoietic Stem Cell Recipients with Sars-CoV-2 Infection in the Midwestern United States: A Multi-Center Retrospective Cohort Study
S. Tanna¹, D. Florescu², A. Majeed³, J. Banzon³, S. Waller⁴, A. Eid⁴, N. Barros Baertl⁵, D. Friedman⁶, K. Mullane⁷, M. Ison⁸
¹Infectious Diseases, Northwestern University Feinberg School of Medicine, Chicago, IL, ²University of Nebraska Medical Center, Omaha, NE, ³Cleveland Clinic, Cleveland, OH, ⁴University of Kansas Medical Center, Overland Park, KS, ⁵Infectious Diseases, Indiana University, Indianapolis, IN, ⁶Infectious Diseases, University of Chicago, Chicago, IL, ⁷University of Chicago, Chicago, IL, ⁸Northwestern University Comprehensive Transplant Center, Chicago, IL
*Purpose: Immunocompromised hosts are at risk for severe complications or death from SARS-CoV-2 infection. Few studies describe the clinical features, outcomes and treatment strategies in…
2022 American Transplant Congress
Seroprevalence of HHV8 Among Donors and Recipients with HIV
P. H. Nambiar¹, T. Liang², J. D. Motter³, W. Werbel³, S. Mehta⁴, V. Kirchner⁵, M. Rana⁶, S. Florman⁷, J. Odim⁸, W. Miley⁹, N. Labo⁹, D. Whitby⁹, A. Massie¹⁰, D. Segev³, A. Tobian³, C. Durand²
¹Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, ²Medicine, Johns Hopkins University, Baltimore, MD, ³Johns Hopkins University, Baltimore, MD, ⁴New York University Langone Transplant Institute, New York, NY, ⁵University of Minnesota, Minneapolis, MN, ⁶Icahn School of Medicine at Mount Sinai, New York, NY, ⁷Mount Sinai Medical Center, New York, NY, ⁸National Institute of Health, Bethesda, MD, ⁹National Cancer Institute, Frederick, MD, ¹⁰Johns Hopkins School of Medicine, Baltimore, MD
*Purpose: Kaposi sarcoma (KS) can develop post-transplant via recipient HHV8 reactivation or donor-acquired HHV8. In the general US population, HHV8 seroprevalence is low (1-5%), yet…
2022 American Transplant Congress
An Analysis of Serological Response and Infection Outcomes Following Oxford Astra-Zeneca (azd1222) and Pfizer-Biontech (mRNA BNT162b2) SARS-CoV-2 Vaccines in Kidney and Pancreas Transplant Patients
A. Asderakis¹, U. Khalid¹, G. Koimtzis¹, M. Ponsford², L. Szabó¹, L. Grant², S. Jolles², I. Humphreys³
¹Cardiff Transplant Unit, University Hospital of Wales, Cardiff, United Kingdom, ²Immunodeficiency Centre for Wales, University Hospital of Wales, Cardiff, United Kingdom, ³Division of Infection and Immunity, Cardiff University, Cardiff, United Kingdom
*Purpose: SARS-CoV-2 is associated with high mortality among transplant recipients. This study aims to compare the humoral responses between the Oxford-Astra-Zeneca(AZ) and BNT162b2(Pfizer-BioNTech) vaccines in…
2022 American Transplant Congress
Prebiotic Supplementation In Kidney Transplant Recipients For Preventing Infections And Gastrointestinal Upset: A Randomized Controlled Feasibility Study
S. Chan¹, C. M. Hawley¹, E. M. Pascoe², C. Z. Cao², S. B. Campbell², K. L. Campbell³, R. S. Francis², R. Hale¹, N. M. Isbel⁴, M. Morrison⁵, D. W. Johnson²
¹Department of Nephrology, Princess Alexandra Hospital, Woolloongabba, Australia, ²Princess Alexandra Hospital, Woolloongabba, Australia, ³Menzies Health Institute - Molecular Basis of Disease Research Program, Griffith University, Brisbane, Australia, ⁴Princess Alexandra Hospital, Brisbane, Australia, ⁵Diamantina Institute, Faculty of Medicine, The University of Queensland, Woolloongabba, Australia
*Purpose: Modulating the large intestinal microbiome of kidney transplant recipients (KTR) may reduce infectious complications. The aim of this study was to assess the feasibility…